In another recent report published in Frontiers in Pharmacology, researchers analyzed Ilumetri using data from the FDA’s adverse event (side-effects) reporting system. Now that the drug has been on the market for 6 years researchers wanted to better understand what the side-effect experience was like. 

The report mentions statistically notable connections between Ilumya and infections, like herpes simplex and vulvovaginal candidiasis, which hadn’t been emphasized in previous clinical trials. There were also connections to cardiac issues like atrial fibrillation and aortic valve incompetence.

As is often the case researchers noted that while they found statistical connections to these side-effects a closer look is needed.